We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Regeneron Pharmaceuticals announced that it will acquire Sanofi’s stake in the Regeneron- Sanofi collaboration on the cancer drug Libtayo (cemiplimab) for $900 million up front, 11 percent royalties on worldwide sales and other milestone payments. Read More
Until a generic version of the drug is available, ViiV will supply Apretude to public programs in “low-income, least-developed and all sub-Saharan African countries” at what it calls a “nonprofit price.” Read More
Johnson & Johnson (J&J) has filed a complaint against Aurobindo Pharma charging the Indian generics maker with infringing on patents for J&J’s blockbuster prostate cancer therapy Erleada (apalutamide). Read More
GSK announced yesterday that it is acquiring Cambridge, Mass.-based biopharma company Affinivax in a $3.3 billion deal, picking up at least two novel pneumococcal vaccine candidates and a promising vaccine technology platform. Read More
Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, plus additional payments for reaching developmental or regulatory milestones. Read More